Valley Fever Solutions is focused first on a Phase-2-ready therapeutic already shown superior to current drugs to treat Valley Fever (VF, coccidioidomycosis). Nikkomycin Z (NikZ) is an antifungal that acts by inhibiting chitin synthase, an MoA unique in antifungals, not known in commercial products or even agents in trials so far as we know. Our reformulation is 30-fold more potent than conventional NikZ therapy. Our reformulation is much easier to administer and should improve convenience and thus patient compliance. "New NikZ"should be powerfully effective in reducing and perhaps eliminating VF in human brains as demonstrated in mice and dogs. Treating 300 patients a year would make this ultra-rare, but suffering patients will be quite grateful. Of course similar benefits should be seen in at least most severe VF cases (800 new cases a year are untreatable) and up to the 50,000 symptomatic patients a year. The new formulation should be more effective against candidemia, and more.